Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Novel Inflammatory Pathways in Chronic Human Liver Diseases

WEBINAR

Only

Novel Inflammatory Pathways in Chronic Human Liver Diseases

Tuesday, October 20, 2020, 10:30 AM - 5:00 PM EDT

The New York Academy of Sciences
7 World Trade Center, New York City, USA

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the world population. Many of these patients subsequently develop non-alcoholic steatohepatitis (NASH), a progressive chronic liver disease for which there is no approved treatment. NASH is projected to be the leading cause of liver failure and transplant in the coming decades. Inflammatory and pro-fibrotic pathways are well established drivers of NASH progression; however, recent work has identified additional cell types as novel regulators of these pathways. Thus, this symposium will focus on less studied immune lineages — such as T helper cells, innate lymphoid cells (ILCs), and natural killer (NK) cells, as well as other non-traditional cell types — including fibroblasts, liver sinusoidal endothelial cells (LSECs), and hepatocytes, which are emerging as critical contributors to NAFLD and NASH. The overarching aim of the meeting is to highlight novel mechanisms that may present new therapeutic targets for chronic liver diseases.

Registration

Member
$30
Nonmember Academia, Faculty, etc.
$65
Nonmember Corporate, Other
$85
Nonmember Not for Profit
$65
Nonmember Student, Undergrad, Grad, Fellow
$45
Member Student, Post-Doc, Fellow
$15

Keynote Speakers

Tim F. Greten, MD
Tim F. Greten, MD

National Cancer Institute

Percy Knolle, MD
Percy Knolle, MD

Technische Universität München

Speakers

Laurie De Leve, MD, PhD

University of Southern California

Jennifer Estall, PhD

McGill University

Mitchell Kronenberg, PhD

La Jolla Institute for Immunology

Paul Kubes, PhD

University of Calgary

Sophie Lotersztajn, PhD

Center for Research on Inflammation, Paris

Naglaa Shoukry, PhD

University of Montreal

Scientific Organizing Committee

Tim F. Greten, MD

National Cancer Institute

Kevin Hart, PhD

Pfizer

Min Wan, PhD

Pfizer

Sara Donnelly, PhD

The New York Academy of Sciences

Sonya Dougal, PhD

The New York Academy of Sciences

Tuesday

October 20, 2020

10:30 AM

Introduction and Welcome Remarks

10:40 AM

Keynote: LSEC regulation of Local Immune Responses in the Liver

Speaker

Percy Knolle, MD
Technische Universität München

Session 1

11:25 AM

Mucosal-Associated Invariant T Cells are a Profiborgenic Immune Cell Population in the Liver

Speaker

Sophie Lotersztajn, PhD
Center for Research on Inflammation, Paris
11:55 AM

Break

12:10 PM

Th17 Type Cytokines in Liver Fibrosis

Speaker

Naglaa Shoukry, PhD
University of Montreal
12:40 PM

iNKT cells Orchestrate a Switch from Inflammation to Resolution of Sterile Liver Injury

Speaker

Paul Kubes, PhD
University of Calgary

Session 2: Data Blitz Talks

1:10 PM

Short talk selected from submitted abstracts

1:25 PM

Short talk selected from submitted abstracts

1:40 PM

Break

2:10 PM

Short Selected From Abstracts

Session 3

2:25 PM

Liver Sinusoidal Endothelial Cells in Chronic Liver Disease

Speaker

Laurie De Leve MD, PhD
University of Southern California
2:55 PM

Hepatocyte Metabolism in Inflammatory Environments

Speaker

Jennifer Estall, PhD
McGill University
3:25 PM

Break

3:40 PM

Subsets of Innate-like T cells in the Liver and Elsewhere

Speaker

Mitchell Kronenberg, PhD
La Jolla Institute for Immunology
4:10 PM

Keynote: Gut Microbiome-Mediated Bile Acid Metabolism Regulates Liver Cancer via NKT Cells

Speaker

Tim F. Greten, MD
National Cancer Institute
4:55 PM

Closing Remarks

5:00 PM

Adjourn